NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Patent Expands Cardiac Monitoring Platform With Heart Failure and Structural Heart Disease Capabilities
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.
To view the full press release, visit https://nnw.fm/jgVf0
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.
To view the full press release, visit https://nnw.fm/jgVf0
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
